Amgen posts Phase 3 trial win for Repatha in major cardiovascular events

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a ...

Amgen claims ‘landmark’ study result that could widen heart drug’s use

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, ...

Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

Amgen: Landmark Phase 3 Trial (vesalius-cv) Meets Primary Endpoints In A Cardiovascular Primary Prevention Study Of 12,000 Patients

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone ...
WebMD

What Is Repatha, and Why Does It Matter?

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
Becker's ASC

FDA broadens Amgen’s Repatha approval for higher-risk patients

The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...